Form 4: Summit Therapeutics Co-CEO's Spouse Exercises Warrants, Acquiring 3,985,055 Shares

Mahkam Zanganeh, Co-CEO of Summit Therapeutics, reports that her spouse exercised warrants to purchase 3,985,055 shares of the company's common stock at $1.58 per share.

Summary

• On April 8, 2025, Mahkam Zanganeh's spouse exercised warrants to acquire 3,985,055 shares of Summit Therapeutics Inc. common stock.
• The exercise price was $1.58 per share.
• Following the transaction, Ms. Zanganeh indirectly owns 555,680,151 shares through her spouse.
• She also has indirect ownership through the Shaun Zanganeh Irrevocable Trust (10,199,776 shares), the Mahkam Zanganeh Revocable Trust (25,457,666 shares), and as an immediate family member (50,000 shares).
• Ms. Zanganeh directly owns 31,000 shares.
• Ms. Zanganeh disclaims beneficial ownership of the indirectly held securities, except to the extent of her pecuniary interest.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing detailing an insider transaction. It doesn't inherently convey positive or negative sentiment.

Management Comments

• The Reporting Person disclaims beneficial ownership of these securities, except to the extent of her pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the trading activities of company insiders.

Stakeholder Impact

• The transaction may have a minor impact on shareholders by slightly increasing the number of outstanding shares.

Key Dates

Keywords

Summit Therapeutics, SMMT, Mahkam Zanganeh, Warrant Exercise, Beneficial Ownership, Form 4, SEC Filing